MD Anderson Cancer Center: Combination Immunotherapy Benefits Subset of Patients With Advanced Prostate Cancer
September 11, 2020
September 11, 2020
HOUSTON, Texas, Sept. 11 (TNSJou) -- The University of Texas's MD Anderson Cancer Center issued the following news release on Sept. 10:
Results from a Phase II trial led by researchers at The University of Texas MD Anderson Cancer Center suggest that a combination of ipilimumab (anti-CTLA-4) plus nivolumab (anti-PD-1) can generate durable responses in a subset of patients with metastatic castration-resistant prostate cancer (mCRPC), an "immune-cold" cancer that does n . . .
Results from a Phase II trial led by researchers at The University of Texas MD Anderson Cancer Center suggest that a combination of ipilimumab (anti-CTLA-4) plus nivolumab (anti-PD-1) can generate durable responses in a subset of patients with metastatic castration-resistant prostate cancer (mCRPC), an "immune-cold" cancer that does n . . .